CATALENT, INC. (NYSE:CTLT) Files An 8-K Other Events
Item8.01
| Other Items. |
On December 2, 2016, Catalent, Inc. (the Company) issued a press
release announcing that its wholly owned subsidiary, Catalent
Pharma Solutions, Inc. (the Operating Company), has priced a
private offering (the Private Offering) of 380.0 million
aggregate principal amount ($404.5 million U.S. dollar
equivalent) of 4.75% senior unsecured notes due 2024 (the Notes)
at par. The full text of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release of Catalent, Inc., dated December 2, 2016, announcing pricing of notes offering. |
About CATALENT, INC. (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services. CATALENT, INC. (NYSE:CTLT) Recent Trading Information
CATALENT, INC. (NYSE:CTLT) closed its last trading session down -0.80 at 23.13 with 953,266 shares trading hands.
